Title
Category
Credits
Event date
Cost
  • Adherence
  • Antipsychotics
  • Cognition
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Learn more in this CME activity.
  • Adherence
  • Antipsychotics
  • Cognition
  • Patient/Physician Communication
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patient-reported outcomes are important for assessing the impact of schizophrenia and the success of treatment. Dr Correll discusses patient-centered care.
  • Adherence
  • Antipsychotics
  • Psychotherapy
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this CME activity, learn how to use patient-centered care to enhance medication adherence and aid functional recovery in schizophrenia.
  • Adherence
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What can you do to combat relapse in your patients with schizophrenia? Dr Lauriello discusses identifying and addressing nonadherence to antipsychotics.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.
  • Antipsychotics
  • Diagnostic Tools
  • Movement Disorders
  • Patient/Physician Communication
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity, Dr Nierenberg describes the evaluation process. 
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients may be more willing to accept some adverse effects than others. Dr Kane offers advice on addressing side effects that prevent patients from maintaining their medication adherence.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotherapy
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Can a patient-centered approach to treatment be adopted for patients with schizophrenia? Can these patients take part in shared decision-making? Follow along as Dr Harvey shares his expertise.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What should you rule out to diagnose tardive dyskinesia (TD)? How do treatment options differ? In this journal CME activity, Drs Citrome and Saklad team up to review the best clinical strategies.
  • Bipolar Disorder
  • Diagnostic Tools
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$10.00
What features may predict bipolar disorder vs schizophrenia in a person with first-episode psychosis? In this journal CME activity, find out which tools could most aid diagnosis.